Elicio Therapeutics Inc.

Plus: Elicio names Preetam Shah CFO and chief strategy officer, and updates from Halozyme, Newron and Skye

BioCentury’s roundup of translational innovations

Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less

Late-stage lead program draws investors’ interest, as does veteran drug-hunting leadership

Plus: Leap, Flame propose merger and updates from Elicio, Angion, Huadong, CARsgen and more 

Plus updates from Elicio, Rejuvenate, Canbridge and more

Companies looking to in-license KRAS inhibitors may need to go early stage 

China-based in-licensing company AffaMed Therapeutics (Shanghai) Co. Ltd. hired Ji Li as president. Li was most recently a venture partner at Lilly Asia Ventures, and prior to that

Pfizer and BioNTech have revealed the clinical data that led the partners to choose which vaccine they would send into Phase III testing for COVID-19. Side-by-side Phase I/II safety and immunogenicity